Using blood test results to help choose blood pressure medicines for high blood pressure
Tests blood-based guidance for picking medicines in adults with high blood pressure.
Plain-language title generated from the registry record
Registry title: Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension
Key facts
- Where
- Hamburg, GermanySee the site
Where in Germany
- University Medical Center Hamburg-EppendorfHamburg, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Birmingham
- Trial code
- NCT07294794
- Record updated
- 19 December 2025
- Original description
High blood pressure (hypertension) affects 1 in 3 adults and can lead to serious health issues like strokes and heart attacks. Medication can lower blood pressure (BP) and reduce complications. Choosing the right medication can be challenging, potentially leading to side effects or poor control.Read full original descriptionShow less
Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension (HYPERMARKER)
High blood pressure (hypertension) affects 1 in 3 adults and can lead to serious health issues like strokes and heart attacks. Medication can lower blood pressure (BP) and reduce complications. Choosing the right medication can be challenging, potentially leading to side effects or poor control.
HYPERMARKER is testing whether providing doctors with additional information when they make a blood pressure prescription choice can improve a patient's overall blood pressure management. This includes relevant clinical information and personalised results from blood tests, brought together using computer programs (machine learning)- 'smart approach'. The blood tests check for small substances naturally produced by the body called metabolites
Developed with patient and public involvement, this proof-of-concept clinical trial will recruit 400 people across four sites in the UK, Spain, the Netherlands, and Germany. Participants must have a recent high blood pressure reading with a clinical need for medication. After providing written consent, they will provide a blood sample (to measure their metabolites) and receive a BP monitor connected to a smartphone app allowing them to measure and record their BP at home throughout the trial.
The study's main outcome is home BP readings. Participants will also complete web-based questionnaires about their health, diet, treatment experience, and healthcare usage.
Participants will be randomly assigned to two groups. Group A will receive medication based on standard clinical practice up-front, then investigators will receive output from the smart approach to refine the choice of treatment. In Group B, investigators will receive the output from the 'smart approach' initially, with further updates provided later.
Only medications licensed for hypertension will be used. All prescriptions are determined by clinicians throughout the trial.
The trial lasts 9-16 weeks. At the end, participants and their usual doctor get a copy of their BP readings and medication to guide their long-term care.
Inclusion: Systolic blood pressure ≥140 mmHg on any blood pressure recording method (office, home or ambulatory); Age 18 years or older; Clinical indication for antihypertensive therapy.
Exclusion: Three or more current anti-hypertensive medications; Potential secondary cause of hypertension, including but not limited to renovascular hypertension, endocrine conditions, chronic kidney disease, coarctation of the aorta or medication related; Planned intervention for hypertension, such as renal denervation; Severe kidney disease (estimated glomerular filtration rate <30 mL/min); Stroke or myocardial infarction within the last 6 months; Diagnosis of known heart failure with left ventricular ejection fraction <40%; Systolic blood pressure ≥180 mmHg on any blood pressure recording method (office, home or ambulatory); Pregnancy, planning for pregnancy, or breastfeeding; Participant whom the Clinical Investigator deems otherwise ineligible.